Literature DB >> 11095838

Current Views on Hepatitis C Virus Infection.

.   

Abstract

Hepatitis C virus infection affects more than 4 million people in the United States and is a leading cause of liver failure necessitating transplantation. Effective combination therapies are now available for subgroups of patients at risk for progression to cirrhosis. The benefits of therapy in immunosuppressed hosts, such as HIV-infected patients and liver transplant recipients, are less well established.

Entities:  

Year:  2000        PMID： 11095838     DOI： 10.1007/s11908-000-0088-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  42 in total

Review 1.  Standards of treatment in chronic hepatitis C.

Authors:  R G Gish
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

2.  Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

Authors:  T Bizollon; U Palazzo; C Ducerf; M Chevallier; M Elliott; J Baulieux; M Pouyet; C Trepo
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

Review 3.  Therapy of hepatitis C: overview.

Authors:  K L Lindsay
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 4.  Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections.

Authors:  H Zylberberg; S Pol
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

Review 5.  Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.

Authors:  D T Dieterich; J M Purow; R Rajapaksa
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 6.  Prevention of hepatitis B and C transmission during pregnancy and the first year of life.

Authors:  M J Freitag-Koontz
Journal:  J Perinat Neonatal Nurs       Date:  1996-09       Impact factor: 1.638

7.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  A pilot study of ribavirin therapy for chronic hepatitis C.

Authors:  A M Di Bisceglie; M Shindo; T L Fong; M W Fried; M G Swain; N V Bergasa; C A Axiotis; J G Waggoner; Y Park; J H Hoofnagle
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.